SCHEMBL2484302

SCHEMBL2484302

CN(C)c1cccc(CNc2cc(Cl)ncc2C(N)=O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 5/20 0.49
JAK2 O60674 3/20 0.49
JAK1 P23458 3/20 0.49
IRAK4 Q9NWZ3 2/20 0.49
TYK2 P29597 2/20 0.49
RPS6KB1 P23443 6/20 0.46
AKT1 P31749 1/20 0.46
EGFR P00533 1/20 0.45
CSF1R P07333 1/20 0.45
BTK Q06187 1/20 0.45
CD38 P28907 2/20 0.44
AURKA O14965 5/20 0.43
AURKB Q96GD4 3/20 0.43
PTK2 Q05397 1/20 0.43
VNN1 O95497 1/20 0.42
GPR52 Q9Y2T5 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
CDC7 O00311 1/20 0.41
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12279847 0.88 JAK3 (0.48) JAK3JAK2JAK1IRAK4TYK2
SCHEMBL2507819 0.88 PTK2 (0.55) JAK3JAK2JAK1IRAK4TYK2
SCHEMBL27828895 0.88 JAK3 (0.45) JAK3JAK2JAK1IRAK4TYK2
SCHEMBL2479562 0.86 RPS6KB1 (0.55) JAK3JAK2JAK1IRAK4TYK2
SCHEMBL2476348 0.86 JAK3 (0.52) JAK3JAK2JAK1IRAK4TYK2
SCHEMBL2482471 0.85 RPS6KB1 (0.60) JAK3JAK2JAK1IRAK4TYK2
SCHEMBL12456033 0.84 RPS6KB1 (0.54) JAK3JAK2JAK1IRAK4TYK2
SCHEMBL2480282 0.84 JAK3 (0.67) JAK3JAK2JAK1IRAK4TYK2
SCHEMBL12206941 0.84 JAK3 (0.55) JAK3JAK2JAK1IRAK4TYK2
SCHEMBL2479688 0.84 RXFP1 (0.47) JAK3JAK2JAK1IRAK4TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110230467-A1 4,6-DIAMINONICOTINAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed
US-20110230467-A1 4,6-DIAMINONICOTINAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230467-A1 4,6-DIAMINONICOTINAMIDE COMPOUND JAK3, JAK2, JAK1 JAK3 1/4885JAK2 2/4885JAK1 3/4885
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA JAK3 1/4885JAK2 4/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.